JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
暂无分享,去创建一个
N. Kröger | A. Heine | P. Brossart | D. Wolf | Kathrin Schönberg | C. Wolschke | T. Stübig | H. Alchalby | I. Cornez | Ioanna Triviai | Sowmya Parampalli Yajnanarayana | J. Rudolph
[1] T. Bieber,et al. Remission of recalcitrant dermatomyositis treated with ruxolitinib. , 2014, The New England journal of medicine.
[2] T. Brümmendorf,et al. The JAK Inhibitor Ruxolitinib Substantially Affects NK Cells in MPN Patients , 2014 .
[3] C. Peschel,et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. , 2014, Blood.
[4] M. Cazzola,et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. , 2014, Blood.
[5] G. Barosi,et al. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib , 2014, Leukemia.
[6] A Caflisch,et al. Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) , 2014, Leukemia.
[7] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[8] J. Dipersio,et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.
[9] J. Dipersio,et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I , 2013, Haematologica.
[10] S. Held,et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. , 2013, Blood.
[11] M. Joel,et al. EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry , 2013, Journal of Neuro-Oncology.
[12] J. Arthur,et al. Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10–Mediated Feedback , 2012, The Journal of Immunology.
[13] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[14] A. Tefferi,et al. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. , 2011, Mayo Clinic proceedings.
[15] J. Fridman,et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. , 2011, The Journal of investigative dermatology.
[16] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[17] W. Paul,et al. Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.
[18] W. Paul,et al. CD4 T cells: fates, functions, and faults. , 2008, Blood.
[19] D. Littman,et al. The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt , 2008, Nature Immunology.
[20] Hua Yu,et al. Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 , 2007, The Journal of Immunology.
[21] D. Levy,et al. JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.
[22] F. Brennan,et al. Expression of Constitutively Active STAT3 Can Replicate the Cytokine-suppressive Activity of Interleukin-10 in Human Primary Macrophages* , 2007, Journal of Biological Chemistry.
[23] M. Farrar,et al. IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.
[24] W. Alexander,et al. General Nature of the STAT3-Activated Anti-Inflammatory Response1 , 2006, The Journal of Immunology.
[25] M. McMullin,et al. The V617F JAK2 mutation and the myeloproliferative disorders , 2005, Hematological oncology.
[26] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[27] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[28] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[29] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[30] T. Mcclanahan,et al. A Receptor for the Heterodimeric Cytokine IL-23 Is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R1 , 2002, The Journal of Immunology.
[31] H. Pircher,et al. Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.
[32] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[33] G. Yancopoulos,et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.
[34] A. Caflisch,et al. Specificity and Mechanism-of-action of the Jak2 Tyrosine Kinase Inhibitors Ruxolitinib and Sar302503 (tg101348) , 2022 .
[35] Jianfei Yang,et al. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells , 2002, Nature Immunology.